JSPR
Jasper Therapeutics, Inc.1.7100
+0.0700+4.27%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
47.85MP/E (TTM)
-Basic EPS (TTM)
-5.82Dividend Yield
0%Recent Filings
8-K
Strong briquilimab urticaria data
Jasper Therapeutics released positive BEACON Phase 1b/2a data on January 8, 2026, showing 67% of additional CSU patients (n=6) achieved complete response at 12 weeks with 31-point mean UAS7 drop; 75% of OLE CSU participants (n=36) hit complete response or well-controlled disease. KIT-related AEs stayed low-grade across 63 patients with 205-day median follow-up. Data clears doses for Phase 2b CSU study in H2 2026. Safety holds firm.
8-K
CEO switch to Jeet Mahal
Jasper Therapeutics ousted CEO Ron Martell effective January 5, 2026, handing reins to COO Jeet Mahal as CEO and President while elevating Chairman Thomas Wiggans to Executive Chair. Martell's exit triggers 18 months base salary severance. Smooth internal transition. Company hosts January 8 webinar on BEACON study data in CSU.
8-K
Positive asthma data, BEACON cleared
Jasper Therapeutics released positive preliminary Phase 1b ETESIAN data on December 2, 2025, showing a single 180mg briquilimab dose cut sputum eosinophils from 1.88% to 0.44% at week 6 in allergic asthma patients while boosting LAR FEV1 by 10.4%. BEACON's anomalous US CSU results stemmed from patient selection—9/10 lacked mast cell-driven disease—no drug issues found. Briquilimab proved well-tolerated. Additional BEACON data due Q1 2026.
8-K
Q3 loss, cash runway extended
Jasper Therapeutics reported Q3 2025 net loss of $18.7M on $50.9M cash, bolstered by a $30M stock/warrant offering extending runway to H1 2026. BEACON study probe cleared drug product of anomalous efficacy issues in key cohorts, shifting focus to site practices. Data from additional patients and OLE due H1 Q1 2026. Cash funds Phase 2b launch mid-2026.
10-Q
Q3 FY2025 results
Jasper Therapeutics held Q3 operating expenses steady at $19.2M, down 4% y/y, while YTD costs jumped 34% y/y to $68.0M on higher program spending before July's 50% workforce cut. Net loss narrowed slightly to $18.7M (Q/Q flat) but widened YTD to $66.7M ($4.18/share on 16.0M diluted shares), with the operating/net gap under 20% despite $2.1M warrant fair-value gain and $2.0M offering costs. Cash burned $55.3M in operating activities YTD (up 33% y/y), ending at $50.9M after $34.6M financing; no debt, capex negligible. September's $27.5M offering added warrants (liability-classified). Restructuring sharpened focus on urticaria trials amid BEACON study probe. Shareholder litigation looms over briquilimab data.
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
CLDX
Celldex Therapeutics, Inc.
26.68-0.41
CRSP
CRISPR Therapeutics AG
55.97-0.28
GRCE
Grace Therapeutics, Inc.
3.34+0.10
HOTH
Hoth Therapeutics, Inc.
1.05-0.04
JBIO
Jade Biosciences, Inc.
16.04+0.79
MRKR
Marker Therapeutics, Inc.
1.27-0.12
SPRO
Spero Therapeutics, Inc.
2.27-0.02
SPRY
ARS Pharmaceuticals, Inc.
10.66+0.07
VERA
Vera Therapeutics, Inc.
48.30-0.91